Pathobiology of pituitary adenomas and carcinomas
- PMID: 16883174
- DOI: 10.1227/01.NEU.0000223437.51435.6E
Pathobiology of pituitary adenomas and carcinomas
Abstract
Objective: To examine relationships between pituitary tumors and lesion size, invasiveness, resectability, deoxyribonucleic acid ploidy, cell cycle profile, mitotic activity, and immunoreactivity for MIB-1, proliferating cell nuclear antigen (PCNA), p27Kip1, and p53.
Patients and methods: One hundred fifty-three adenomas of most pathological subtypes, including 20 medically treated and prolactin and growth hormone-containing tumors, as well as 10 premetastatic tumors and 13 pituitary carcinomas, were studied.
Results: Significant (P < 0.05) differences were noted between functional versus nonfunctional adenomas (percent aneuploidy, percent S phase, p27Kip1 labeling indices [LI], male sex, tumor size, and frequency of visual disturbance); Cushing's versus silent adrenocorticotropin adenomas (percent hypertetraploidy, p53 LI, tumor size, visual disturbance, and resectability); untreated versus medically treated prolactin cell adenomas (MIB-1 LI, p53 LI, and resectability); untreated versus medically treated growth hormone-containing adenomas (percent diploidy, percent S phase, MIB-1 LI, p53 LI, and p27 LI); untreated prolactin cell adenomas versus premetastatic tumors (percent hypertetraploidy, PCNA LI, p53 LI, invasiveness, and resectability); untreated growth hormone-containing adenomas versus premetastatic tumors (percent diploidy, percent S phase, PCNA LI, p53 LI, invasiveness, and resectability); Cushing's adenomas versus premetastatic tumors (percent diploidy, percent hypertetraploidy, percent S phase, MIB-1 LI, p53 LI, tumor size, invasiveness, visual disturbance, and resectability); Nelson's adenomas versus premetastatic tumors (p53 LI, tumor size, invasiveness, and resectability); silent adenomas as a whole versus nonfunctional adenomas (percent nondiploid, percent S phase, invasiveness, and respectability); silent adrenocorticotropin adenomas I and II versus silent adenoma Subtype III (invasiveness); silent adrenocorticotropin adenoma Subtypes I and II versus premetastatic tumors (MIB-1 LI and invasiveness); silent adenoma Subtype III versus premetastatic tumors (PCNA and p53 LI); and premetastatic tumors versus metastatic pituitary carcinomas (MIB-1 LI).
Conclusion: Only trends toward differences were noted between Cushing's versus Nelson's adenomas and between prolactinomas of reproductive female patients versus those of menopausal female patients and male patients. Too few "atypical adenomas" were encountered to permit their comparison with premetastatic tumors, but our results suggest that most pituitary carcinomas arise by malignant transformation from adenomas.
Similar articles
-
Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.Exp Clin Endocrinol Diabetes. 2008 Feb;116(2):80-5. doi: 10.1055/s-2007-991131. Epub 2007 Dec 10. Exp Clin Endocrinol Diabetes. 2008. PMID: 18072009
-
Predictive markers of pituitary adenoma behavior.Neuroendocrinology. 2006;83(3-4):179-88. doi: 10.1159/000095526. Epub 2006 Oct 13. Neuroendocrinology. 2006. PMID: 17047381 Review.
-
Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.Acta Neurochir (Wien). 2004 Aug;146(8):831-9. doi: 10.1007/s00701-004-0298-0. Epub 2004 Jun 14. Acta Neurochir (Wien). 2004. PMID: 15254805
-
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.Cancer. 2002 Apr 15;94(8):2151-9. doi: 10.1002/cncr.10458. Cancer. 2002. PMID: 12001111 Review.
-
p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1. Neurosurgery. 1996. PMID: 8692397
Cited by
-
Microvascular Changes in Pituitary Adenoma Correlate with Structural Measurements and Visual Field Loss.Neuropsychiatr Dis Treat. 2023 Dec 6;19:2745-2754. doi: 10.2147/NDT.S425454. eCollection 2023. Neuropsychiatr Dis Treat. 2023. PMID: 38090020 Free PMC article.
-
Hypogonadism in Male Patients with Pituitary Adenoma and Its Related Mechanism: A Review of Literature.Brain Sci. 2022 Jun 17;12(6):796. doi: 10.3390/brainsci12060796. Brain Sci. 2022. PMID: 35741681 Free PMC article. Review.
-
Connexin Expression in Pituitary Adenomas and the Effects of Overexpression of Connexin 43 in Pituitary Tumor Cell Lines.Genes (Basel). 2022 Apr 12;13(4):674. doi: 10.3390/genes13040674. Genes (Basel). 2022. PMID: 35456480 Free PMC article.
-
Pituitary adenoma or pituitary neuroendocrine tumor: a narrative review of controversy and perspective.Transl Cancer Res. 2021 Apr;10(4):1916-1920. doi: 10.21037/tcr-20-3446. Transl Cancer Res. 2021. PMID: 35116513 Free PMC article. Review.
-
Pituitary Carcinoma in a Patient with Cowden Syndrome.Am J Case Rep. 2022 Feb 3;23:e934846. doi: 10.12659/AJCR.934846. Am J Case Rep. 2022. PMID: 35110519 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous